Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Leukemia

  Free Subscription


11.10.2021

1 Ann Hematol
2 Blood
1 BMJ
2 Bone Marrow Transplant
1 Cancer
2 Int J Hematol
1 J Clin Oncol
3 Leuk Lymphoma
8 Leukemia
1 PLoS One


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Ann Hematol

  1. UMINSKI K, Khalife R, Fulcher J, Duffett L, et al
    Acquired factor V deficiency in the setting of mercaptopurine therapy for acute lymphoblastic leukemia.
    Ann Hematol. 2021 Oct 6. pii: 10.1007/s00277-021-04688.
    PubMed        


    Blood

  2. FISHMAN H, Madiwale S, Geron I, Bari V, et al
    ETV6-NCOA2 fusion induces T/Myeloid mixed-phenotype leukemia by transformation of non-thymic hematopoietic progenitors.
    Blood. 2021 Oct 8. pii: 477216. doi: 10.1182/blood.2020010405.
    PubMed         Abstract available

  3. PROSSER AL, Li W
    Salmon-colored granules in the leukemic blasts of B-lymphoblastic leukemia with iAMP21.
    Blood. 2021;138:1282.
    PubMed        


    BMJ

  4. NEWELL LF, Cook RJ
    Advances in acute myeloid leukemia.
    BMJ. 2021;375:n2026.
    PubMed         Abstract available


    Bone Marrow Transplant

  5. MASOURIDI-LEVRAT S, Olavarria E, Iacobelli S, Aljurf M, et al
    Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Workin
    Bone Marrow Transplant. 2021 Oct 1. pii: 10.1038/s41409-021-01472.
    PubMed         Abstract available

  6. POIRE X, Graux C, Ory A, Herman J, et al
    Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): a prospective s
    Bone Marrow Transplant. 2021 Oct 5. pii: 10.1038/s41409-021-01464.
    PubMed        


    Cancer

  7. KANTARJIAN HM, Jain N, Garcia-Manero G, Welch MA, et al
    The cure of leukemia through the optimist's prism.
    Cancer. 2021 Oct 6. doi: 10.1002/cncr.33933.
    PubMed         Abstract available


    Int J Hematol

  8. NUKUI J, Tanaka M, Nakajima H
    A case of multiple brain abscesses due to Bacillus cereus during induction therapy for acute myeloid leukemia.
    Int J Hematol. 2021 Oct 7. pii: 10.1007/s12185-021-03226.
    PubMed        

  9. LEE SH, Yoon JH, Min GJ, Park SS, et al
    Response to blinatumomab or inotuzumab ozogamicin for isolated extramedullary relapse of adult acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation: a case study.
    Int J Hematol. 2021 Oct 6. pii: 10.1007/s12185-021-03231.
    PubMed         Abstract available


    J Clin Oncol

  10. WIERDA WG, Allan JN, Siddiqi T, Kipps TJ, et al
    Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
    J Clin Oncol. 2021 Oct 7:JCO2100807. doi: 10.1200/JCO.21.00807.
    PubMed         Abstract available


    Leuk Lymphoma

  11. NACHMIAS B, Rund D
    p53 in Acute Myeloid Leukemia-Still a significant other.
    Leuk Lymphoma. 2021 Oct 5:1-3. doi: 10.1080/10428194.2021.1988592.
    PubMed        

  12. XUE S, Zhang Y, Liu F, Huang W, et al
    Olaparib combined with chemotherapy for treatment of T-cell acute lymphoblastic leukemia relapse after unrelated umbilical cord blood transplantation.
    Leuk Lymphoma. 2021 Oct 5:1-5. doi: 10.1080/10428194.2021.1984453.
    PubMed        

  13. AGIUS R, Parviz M, Niemann CU
    Artificial intelligence models in chronic lymphocytic leukemia - recommendations toward state-of-the-art.
    Leuk Lymphoma. 2021 Oct 6:1-14. doi: 10.1080/10428194.2021.1973672.
    PubMed         Abstract available


    Leukemia

  14. GODWIN CD, Laszlo GS, Fiorenza S, Garling EE, et al
    Targeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapy.
    Leukemia. 2021;35:2496-2507.
    PubMed         Abstract available

  15. AL HINAI ASA, Grob T, Rijken M, Kavelaars FG, et al
    PPM1D mutations appear in complete remission after exposure to chemotherapy without predicting emerging AML relapse.
    Leukemia. 2021;35:2693-2697.
    PubMed        

  16. ROLLIG C, Serve H, Noppeney R, Hanoun M, et al
    Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial.
    Leukemia. 2021;35:2517-2525.
    PubMed         Abstract available

  17. ZHAO LP, Boy M, Azoulay C, Clappier E, et al
    Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease.
    Leukemia. 2021;35:2720-2724.
    PubMed        

  18. HEYES E, Schmidt L, Manhart G, Eder T, et al
    Identification of gene targets of mutant C/EBPalpha reveals a critical role for MSI2 in CEBPA-mutated AML.
    Leukemia. 2021;35:2526-2538.
    PubMed         Abstract available

  19. GIONFRIDDO I, Brunetti L, Mezzasoma F, Milano F, et al
    Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML.
    Leukemia. 2021;35:2552-2562.
    PubMed         Abstract available

  20. ISSA GC, Ravandi F, DiNardo CD, Jabbour E, et al
    Therapeutic implications of menin inhibition in acute leukemias.
    Leukemia. 2021;35:2482-2495.
    PubMed         Abstract available

  21. ZHAO LP, Schell B, Sebert M, Kim R, et al
    Prevalence of UBA1 mutations in MDS/CMML patients with systemic inflammatory and auto-immune disease.
    Leukemia. 2021;35:2731-2733.
    PubMed        


    PLoS One

  22. MOSQUERA ORGUEIRA A, Ferreiro Ferro R, Diaz Arias JA, Aliste Santos C, et al
    Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes.
    PLoS One. 2021;16:e0248886.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: